Covid-19: why Novavax could convince those who are hesitant about vaccination

DECRYPTION – While nearly 4 million French people over the age of 12 have not yet received a single dose, the fifth vaccine authorized in Europe is expected in the coming days.

Nearly 4 million French people over the age of 12 have not yet received the slightest injection of an anti-Covid vaccine. It is in particular for this population that the Novavax vaccine is intended, the first deliveries of which are planned for this week in France. 1.14 million doses are expected, including 600,000 reserved for overseas, where the vaccination rate remains low. In total, 3.2 million doses of Nuvaxovid are expected in France in the first quarter, and 3.2 million additional doses from the second quarter.

The Novavax vaccine, which has the advantage of being able to be stored in a conventional refrigerator, is based on recombinant protein. This is a classic technology – unlike messenger RNA – already used in vaccines against whooping cough or hepatitis B. “It will be offered in a vaccination center as a priority, but city effectors will be able to obtain the vaccine from the centers that will be equipped with it”details the Ministry of…

This article is for subscribers only. You have 78% left to discover.

Pushing back the limits of science is also freedom.

Keep reading your article for 1€ the first month

Already subscribed? Login


Leave a Reply

Your email address will not be published. Required fields are marked *